Acetamidine

Acetamidine

SCHEMBL6287555

CC(=N)N.COS(=O)(=O)O

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3

The experimentally established mechanism targets of Acetamidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 3/20 0.43
KDM4E B2RXH2 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CA2 P00918 3/20 0.40
CA1 P00915 2/20 0.40
TSHR P16473 3/20 0.35
USP2 O75604 1/20 0.35
NT5E P21589 1/20 0.32
CA4 P22748 1/20 0.32
CA6 P23280 1/20 0.32
CA5A P35218 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA5B Q9Y2D0 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
LMNA P02545 1/20 0.32
ALOX15 P16050 1/20 0.32
PMP22 Q01453 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanidine SCHEMBL3047699 0.91 KDM4E (0.46) BLMKDM4ECYP2D6CYP2C19NPSR1
Thiourea SCHEMBL7362564 0.86 KDM4E (0.42) BLMKDM4ECYP2D6CYP2C19NPSR1
SCHEMBL6737394 0.86 KDM4E (0.42) BLMKDM4ECYP2D6CYP2C19NPSR1
Acetamide SCHEMBL6843069 0.85 BLM (0.50) BLMKDM4ECYP2D6CYP2C19NPSR1
SCHEMBL6285161 0.82 CA2 (0.35) BLMKDM4ECYP2D6CYP2C19NPSR1
SCHEMBL6286669 0.81 KDM4E (0.39) BLMKDM4ECYP2D6CYP2C19NPSR1
SCHEMBL6289391 0.81 KDM4E (0.39) BLMKDM4ECYP2D6CYP2C19NPSR1
Methylamine SCHEMBL143865 0.81
Sulfuric Acid SCHEMBL689483 0.81
Hydrazine SCHEMBL679587 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043403-A1 N-unsubstituted amidinium salts KRAUS HELMUT (DE) 2005-02-24 US claimed
US-20030060653-A1 N-unsubstituted amidinium salts BAYER AKTIENGESELLSCHAFT (DE) 2003-03-27 US claimed
EP-1288197-A2 N-Unsubstituted amidinium salts Bayer Aktiengesellschaft (DE) 2003-03-05 EP claimed
US-20050043403-A1 N-unsubstituted amidinium salts KRAUS HELMUT (DE) 2005-02-24 US disclosed
US-6841696-B2 N-unsubstituted amidinium salts BAYER AKTIENGESELLSCHAFT (DE) 2005-01-11 US disclosed
US-20030060653-A1 N-unsubstituted amidinium salts BAYER AKTIENGESELLSCHAFT (DE) 2003-03-27 US disclosed
EP-1288197-A2 N-Unsubstituted amidinium salts Bayer Aktiengesellschaft (DE) 2003-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060653-A1 N-unsubstituted amidinium salts ASNS, ASS1, STS BLM 4425/4885KDM4E 1148/4885CYP2D6 1207/4885
US-20050043403-A1 N-unsubstituted amidinium salts ASNS, ASS1, STS BLM 4425/4885KDM4E 1148/4885CYP2D6 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.